Ferring Pharmaceuticals, Inc.
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 513
- Registration Number
- NCT01956123
- Locations
- 🇮🇹
Centro Natalità San Raffaele (there may be other sites in this country), Milano, Italy
🇨🇦Pacific Centre for Reproductive Medicine, Burnaby, British Columbia, Canada
🇨🇿IVF CUBE SE (there may be other sites in this country), Prague, Czechia
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 1329
- Registration Number
- NCT01956110
- Locations
- 🇫🇷
Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre (there may be other sites in this country), Lille, France
🇨🇦Ottawa Fertility Centre, Ottawa, Ontario, Canada
🇵🇱The nOvum Clinic (there may be other sites in this country), Warszawa, Poland
Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy
- Conditions
- Need for Bowel Preparation
- Interventions
- Drug: Oral polyethylene glycol (PEG) based preparation (13-16 years)Drug: Prepopik® ½ Sachet x 2 (9-12 years)Drug: Prepopik® 1 Sachet x 2 (9-12 years)Drug: Oral polyethylene glycol (PEG) based preparation (9-12 years)Drug: Prepopik® 1 Sachet x 2 (13-16 years)
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT01928862
- Locations
- 🇺🇸
University California San Diego - Rady's Children's Hospital, San Diego, California, United States
🇺🇸IU Medical Center / Riley Hospital, Indianapolis, Indiana, United States
🇺🇸John Hopkins, Baltimore, Maryland, United States
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females
- Conditions
- Anovulation
- Interventions
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT01923194
- Locations
- 🇨🇳
Navy General Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT01922193
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
🇨🇳Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 411
- Registration Number
- NCT01895543
- Locations
- 🇺🇸
Meridien Research, Bradenton, Florida, United States
🇨🇦Prime Health Clinical Research Organization (there may be other sites in this country), Toronto, Ontario, Canada
🇺🇸Palm Beach Research Center, West Palm Beach, Florida, United States
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
- Conditions
- Advanced Hormone Dependent Prostate Cancer
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT01861236
- Locations
- 🇦🇷
Hospital de Trauma y Emergencia Dr Federico Abete, Ingeniero Pablo Nogués, Buenos Aires, Argentina
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 314
- Registration Number
- NCT01833065
- Locations
- 🇺🇸
David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Zasa Clinical Research, Boynton Beach, Florida, United States
🇺🇸Meridien Research, Bradenton, Florida, United States
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT01827592
- Locations
- 🇧🇪
Huisartspraktijk Jaak Mortelmans, Ham, Belgium
🇺🇸ActivMed Practices and Research, Inc., Newington, New Hampshire, United States
🇮🇱Sheba Medical Center, Tel Hashomer, Israel
Daytime Impact Sleep Study
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT01779466
- Locations
- 🇬🇧
Surrey Clinical Research Centre, Surrey, United Kingdom